News & Updates

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

In patients with metabolic dysfunction and alcohol-related liver disease (MetALD), persistent binge drinking history is a risk factor for advanced fibrosis and mortality, according to a study.

In patients with nonmetastatic hepatocellular carcinoma (HCC), treatment with upfront liver transplant or liver transplant with bridge systemic therapy results in significantly better improvements in overall survival (OS) compared with systemic therapy only, according to a study.

Patients who discontinue tenofovir alafenamide (TAF) therapy appear to have a higher hepatitis B virus relapse rate than those who ceased entecavir or tenofovir disoproxil fumarate (TDF) therapy, according to a recent study.

Patients with cirrhosis using calcium channel blockers (CCBs) are not at increased risk of variceal haemorrhage, as reported in a retrospective study.

Patients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction–associated fatty liver disease (MAFLD) have an elevated risk of nephrolithiasis, according to a study.

Chronic hepatitis C virus (HCV) infection contributes to an increased risk of pancreatic ductal adenocarcinoma (PDAC), as reported in a retrospective study.

In advanced biliary tract cancer (BTC), progression-free survival (PFS) is moderately associated with overall survival (OS) both the trial- and patient-level analyses, while objective response rate (ORR) and disease control rate (DCR) show a low correlation.

A 3-year update from the phase III TOPAZ-1 study has shown sustained survival benefit and manageable safety with durvalumab plus gemcitabine and cisplatin (GemCis) relative to placebo among patients with advanced biliary tract cancer (BTC).

Treatment with rivaroxaban appears to improve portal hypertension (PHT)-related complications without increasing the risk of major bleeding in patients with cirrhosis and moderate liver dysfunction, a study has shown.